FDA Announces Members of Compounding Advisory Committee

Committee Includes Only One Compounding Pharmacist

The U.S. Food and Drug Administration (FDA) announced the membership of its Pharmacy Compounding Advisory Committee. The committee comprises 14 members, 12 voting and two non-voting, who will provide advice on scientific, technical and medical issues concerning drug compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Only one member of the committee is a practicing compounding pharmacist and is a non-voting member. In a news release, International Acadmey of Compounding Pharmacists' Executive Vice President/CEO David G. Miller, RPh, said: "We are glad to see that the FDA has put the Pharmacy Compounding Advisory Committee in place and we hope that this process will result in an implementation of DQSA that is more consistent with the intent of the law. While we are pleased that the advisory committee finally has been announced and that the members are well-qualified scientifically, IACP has serious concerns about the lack of representation on the panel of actual practicing compounding pharmacists. IACP submitted 24 nominees, many with extensive real-life compounding practice experience, to the FDA and only one was selected."